Info

🌱 來自: Metastatic Colon Cancer

FIRE-3

• FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
• 28.7 months (95% CI 24·0-36·6) in the cetuximab group compared with 25.0 months (22·7-27·6) in the bevacizumab group